How to use the FDA Inactive Ingredient Database (IID)

CDER Small Business and Industry Assistance
Generic Drug Forum
April 13, 2016

Susan Zuk
CDER Excipient Working Group Lead
Office of Policy for Pharmaceutical Quality
OPQ, CDER, FDA

OFFICE OF PHARMACEUTICAL QUALITY

Sources of Confusion

Ingredient names

Maximum potency

Numerous potencies

Changes


D1S4 - Sources of Confusion
View Votes
Edit
End Poll
Which of these topics is of most concern to you?
Ingredient Names 0% (0)
Maximum Potency 0% (0)
Numerous Potencies 0% (0)
Changes 0% (0)

Outline

- What is in the IID?
- IID Search
- Ingredient names
- Maximum potency
- How does it work?
- Application review
- Important considerations
- Changes
- Summary

Product Development Dilemma



“What can I use in my formula?”

Use the IID

- Searchable list
- Inactive ingredients in approved products
- Maximum levels
- Toolbox for development

Evidence of Safe Use

- Once an ingredient is used in an approved drug product, it is no longer considered new
  - For a specific route of administration
- Can be consider safe
  - Used in a similar manner
  - For a similar type of product
  - Within listed potency (amount)

http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
<select> About this Database

What is in the IID?

1. Ingredient name
2. Route of administration
3. Dosage form
4. CAS number
5. UNII code
6. Maximum potency

http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm


U.S. Department of Health and Human Services
U.S. Food and Drug Administration
Protecting and Promoting Your Health
A to Z Index | Follow FDA | En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Home > Drug Databases > Inactive Ingredient Search
Inactive Ingredient Search for Approved Drug Products
About this Database
Search for an inactive ingredient
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: October 12, 2015
Database Last Updated: November 25, 2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Accessibility
Careers
FDA Basics
FOIA
No Fear Act
Site Map
Transparency
Website Policies

Example of an IID Search

Inactive Ingredient Search for Approved Drug Products

About this Database (http://www.fda.gov/Drugs/InformationOn-Drugs/ucm080123.htm)

Polyethylene glycol 6000

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov (mailto:IIDUpdate@fda.hhs.gov)
Update Frequency: Quarterly
Data Through: October 12, 2015
Database Last Updated: November 25, 2015

Example of an IID Search

polyethylene glycol 6000

Substance Registration System (SRS) Preferred Name and UNII

Inactive Ingredient	Route	Dosage Form	CAS Number	UNII	Maximum Potency
POLYETHYLENE GLYCOL 6000	BUCCAL/SUBLINGUAL	TABLET	25322683	30IQX730WE	70MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE	25322683	30IQX730WE	10MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, DELAYED ACTION	25322683	30IQX730WE	4.43MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, DELAYED ACTION, ENTERIC COATED, HARD GELATIN	25322683	30IQX730WE	0.57MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, EXTENDED RELEASE	25322683	30IQX730WE	18.88MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, HARD GELATIN	25322683	30IQX730WE	450MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, SUSTAINED ACTION	25322683	30IQX730WE	17.46MG
POLYETHYLENE GLYCOL 6000	ORAL	TABLET	25322683	30IQX730WE	375MG

Ingredient Names

IID Uses the Substance Registration System (SRS)



Tips for Searching

1. IID ingredient names come from SRS
2. IID does not list trade names, usually
3. Always check SRS for the preferred name first
4. Then search IID using the preferred name

http://fdasis.nlm.nih.gov/srs/srs.jsp

Example of an IID Search

polyethylene glycol 6000

Inactive Ingredient	Route	Dosage Form	CAS Number	UNII	Maximum Potency
POLYETHYLENE GLYCOL 6000	BUCCAL/SUBLINGUAL	TABLET	25322683	30IQX730WE	70MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE	25322683	30IQX730WE	10MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, DELAYED ACTION	25322683	30IQX730WE	4.43MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, DELAYED ACTION, ENTERIC COATED, HARD GELATIN	25322683	30IQX730WE	0.57MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, EXTENDED RELEASE	25322683	30IQX730WE	18.88MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, HARD GELATIN	25322683	30IQX730WE	450MG
POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, SUSTAINED ACTION	25322683	30IQX730WE	17.46MG
POLYETHYLENE GLYCOL 6000	ORAL	TABLET	25322683	30IQX730WE	375MG

Highest Level per Unit Dose

What is Maximum Potency?

Maximum potency = Highest amount per unit dose

DOSAGE FORM	UNITS
SOLID ORAL  	X MG (unit dose)
LIQUID ORAL 	X MG/X ML (unit dose)
TOPICALS 	%W/W, %W/V, %V/V
PARENTERALS 	% (W/V)
TDS 	MG (per system)

How Do Ingredients Get Into the IID?

3.2.P.1
unit dose
composition

Master Database



Ingredient query

- Is it new?
- Is the potency > IID?
- Is it a new route?
- Is it a new dosage form?

New IID Entry

Using IID Information in an ANDA

Hypothetical generic product
DS tablets 100 mg
Maximum Daily Dose (MDD): 2 tablets

Ingredient	Function	Amount per tablet (mg)	% W/W
Drug substance (DS)	active ingredient	100 mg	20% W/W
Polyethylene glycol 6000	diluent	400 mg	80% W/W
Total tablet weight		500 mg	100% W/W

Is the amount of excipient per unit dose within IID? **Yes**

POLYETHYLENE GLYCOL 6000	ORAL	CAPSULE, HARD GELATIN	25322683	30IQX730WE	450MG

Using IID Information in an ANDA

Is the maximum daily intake of the excipient higher than previously approved products?

MDD = 2 tablets = 800 mg = maximum daily intake (MDI)

- IID does not provide maximum daily intake
- There is uncertainty of FDA acceptance
- Approvability will be determined in the scientific review

Some options to support the application

1. Control Correspondence
2. Safety data - pharmacology/toxicology
3. Reference to approved products with higher amounts

Important Considerations

- Consider context of use
- Consider patient population
- Consider known adverse effects
- Know the excipient
  - Potential clinical effects
  - Residual solvents
  - Impurities
  - Interactions



What's Not in the IID?

- Inactive ingredients in BLAs
- Active ingredients
- Reagents
- Processing aids
- Solvents that are removed through processing
- Source application numbers
- Approval dates

Changes to the IID

Summary

- Reference the IID
- Use SRS for ingredient names
- Maximum potency = highest amount per unit dose
- Approvability of maximum daily intake (MDI) is part of the scientific review
- Concerns about MDI can be addressed through controlled correspondence
- Consider suitability of the excipient for the product

Contact Information

- Corrections and questions about the IID
  IIDUpdate@fda.hhs.gov

- Corrections and questions about SRS preferred names
  fda-srs@fda.hhs.gov

- Questions about excipients in development of generic products: Controlled Correspondence
  GenericDrugs@fda.hhs.gov

Acknowledgments

Mohamed Ghorab, OPPQ, OPQ, CDER
Ashley Boam, OPPQ, OPQ, CDER
CDER Excipient Working Group

Special thanks to
Johnny Young and Julia Lee, OGD, CDER

Thank you

Questions?

surveymonkey.com/r/GDF-D1S4